Description

Gaudium IVF and Women Health Limited (ticker: 544709) will be added to the BSE IPO Index effective March 4, 2026, following its listing on BSE on February 27, 2026.

Summary

BSE Index Services Private Limited has announced the addition of Gaudium IVF and Women Health Limited (Exchange ticker: 544709) to the BSE IPO Index. The company was listed on BSE effective February 27, 2026, and will be included in the index from the open of trading on Wednesday, March 4, 2026.

Key Points

  • Gaudium IVF and Women Health Limited (ticker: 544709) listed on BSE on February 27, 2026
  • The stock will be added to the BSE IPO Index effective at open on March 4, 2026
  • This action follows reference Notice No. 20260226-41
  • The corporate action will be included in the end-of-day corporate action file (*.SDE) on February 27, 2026
  • Queries may be directed to bseindex@bseindia.com

Regulatory Changes

No regulatory changes. This is a routine index rebalancing action by BSE Index Services Private Limited following the listing of a new IPO on the exchange.

Compliance Requirements

  • Index fund managers and ETF operators tracking the BSE IPO Index must update their portfolios to include 544709 (Gaudium IVF and Women Health Limited) by the open of March 4, 2026
  • Clients with index-related strategies should review their systems for the updated end-of-day corporate action file (*.SDE)

Important Dates

  • February 27, 2026: Listing of Gaudium IVF and Women Health Limited on BSE; corporate action file updated
  • March 4, 2026 (market open): Effective date for addition to the BSE IPO Index

Impact Assessment

This addition will impact portfolios and funds that track or benchmark against the BSE IPO Index. Index-tracking products will need to incorporate the new constituent. The broader market impact is limited, as this is a standard post-IPO index inclusion process. Passive investors in BSE IPO Index-linked instruments should expect minor portfolio rebalancing activity ahead of the March 4, 2026 effective date.

Impact Justification

Routine index addition following a new IPO listing; affects index-tracking funds and ETFs referencing the BSE IPO Index, but is limited in broader market impact.